Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-CTR-FAPI in advanced metastatic digestive malignancies
NCT07014254Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label, single-arm trial of 177Lu-CTR-FAPI in pancreatic ductal adenocarcinoma (PDAC), gastric adenocarcinoma, metastatic colorectal cancer (mCRC) and 4 more, sponsored by Xijing Hospital. Primary endpoints: Objective Response Rate at 12 weeks and Disease Control Rate at 12 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
177Lu-CTR-FAPI
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)gastric adenocarcinomametastatic colorectal cancer (mCRC)Neuroendocrine Neoplasm (NEN)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07014254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014254.